MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Long term control of gout

 December 2014: Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity.

 July 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease.

NICE guidance

See individual NICE guidance for drugs below

Allopurinol:

This is the drug of choice for prophylaxis. It should not be started during an acute attack but 1-2 weeks after the attack has settled. The initiation of allopurinol may precipitate an acute attack, so an NSAID or low dose colchicine (500mcg 1 - 2 times daily) should be used as a prophylactic and continued for at least 1 month after the hyperuricaemia has been corrected.

Febuxostat:

This is a non-purine, xanthine oxidase inhibitor licensed for the treatment of chronic hyperuricaemia in adults, in whom urate deposition has already occured (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat has been approved by NICE for use in patients with gout where allopurinol is contraindicated or not tolerated, (but take great care if the patient has a history of hypersensitivity to allopurinol - see warning above).

Crystallisation of urate in the urine can occur with uricosuric drugs below, therefore it is important to ensure adequate urine output in the first few weeks of treatment.

Aspirin and other salicylates antagonise uricosuric drugs, and so are not indicated in gout.

Pack Price
28 tablet £1.77
Pack Price
28 tablet (2 x 14 tablets) £4.50
Pack Price
100 tablet
30 tablet